Answers are grounded in this paper and cite their sources.
OBJECTIVE: To investigate the short-term clinical efficacy and safety of the Janus kinase inhibitor tofacitinib in patients with Nagashima-type palmoplantar keratoderma (NPPK). METHODS: A retrospective analysis was performed on 7 NPPK patients with a homozygous SERPINB7 c.796C>T mutation, treated with oral tofacitinib citrate (adults: 5 mg twice daily; children: 5 mg once daily). Efficacy and adverse events were evaluated at weeks 0, 4, 8, and 12. RESULTS: The cohort included 5 female and 2 male patients, including 2 children. The mean age at disease onset was 15.3 years, with onset at ≤ 10 years in 5 patients. All had palmoplantar keratosis; 2 had Achilles tendon and 3 wrist involvement. All patients had ineffective prior retinoid therapy. No adverse events occurred during tofacitinib treatment. Hyperkeratosis improved markedly in 4 (57%), mildly in 1 (14%), and showed no response in 2 (29%) patients. The mean keratotic severity score decreased from 6.89 to 4.25 (approx. 40% reduction). CONCLUSIONS: Tofacitinib may be effective for NPPK, but larger randomized controlled trials are required to confirm long-term efficacy and safety.
No takes yet. Share an insight, caveat, or question.
徐东昭 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: